Relevant bibliographies by topics / Neutralizing antibodies

Academic literature on the topic 'Neutralizing antibodies'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neutralizing antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Neutralizing antibodies"

1

Vinson, Valda. "Protective neutralizing antibodies." Science 369, no. 6506 (August 20, 2020): 930.13–932. http://dx.doi.org/10.1126/science.369.6506.930-m.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dempsey, Laurie A. "Zika-neutralizing antibodies." Nature Immunology 18, no. 6 (June 2017): 603. http://dx.doi.org/10.1038/ni.3762.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bell, Elaine. "Neutralizing antibodies revisited." Nature Reviews Immunology 2, no. 6 (June 2002): 387. http://dx.doi.org/10.1038/nri833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Muharemagic, D., A. S. Zamay, S. M. Ghobadloo, J. C. Bell, and M. V. Berezovski. "APTAMER-FACILITATED PROTECTION OF ONCOLYTIC VIRUS FROM NEUTRALIZING ANTIBODIES." Siberian Medical Review, no. 5 (2016): 116. http://dx.doi.org/10.20333/25000136-2016-5-116-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kadkhoda, Kamran. "COVID ‐19: are neutralizing antibodies neutralizing enough?" Transfusion 60, no. 7 (June 3, 2020): 1602–3. http://dx.doi.org/10.1111/trf.15897.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bjorkman, Pamela. "Neutralizing antibodies against coronaviruses." Microscopy and Microanalysis 27, S1 (July 30, 2021): 1112–13. http://dx.doi.org/10.1017/s1431927621004177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Noronha, A. "Neutralizing antibodies to interferon." Neurology 68, Issue 24, Supplement 4 (June 11, 2007): S16—S22. http://dx.doi.org/10.1212/01.wnl.0000277705.63813.84.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Corti, Davide, and Antonio Lanzavecchia. "Broadly Neutralizing Antiviral Antibodies." Annual Review of Immunology 31, no. 1 (March 21, 2013): 705–42. http://dx.doi.org/10.1146/annurev-immunol-032712-095916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grauer, A., H. Reinel, R. Ziegler, and F. Raue. "Neutralizing Antibodies Against Calcitonin." Hormone and Metabolic Research 25, no. 09 (September 1993): 486–88. http://dx.doi.org/10.1055/s-2007-1002156.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

O'Connell, Nicola, and Bronwen Roper. "Testing for neutralizing antibodies." British Journal of Neuroscience Nursing 3, no. 2 (February 2007): 65–67. http://dx.doi.org/10.12968/bjnn.2007.3.2.23140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Neutralizing antibodies"

1

Ovcina, Emira. "An immune response to peptides selected with neutralizing antibodies." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0019/MQ59191.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bonsall, David George. "The role of neutralizing antibodies in HIV-1 infection." Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/6360.

Full text
Abstract:
Human immunodeficiency virus type 1 is a major cause of morbidity and mortality worldwide and there is urgent demand for a protective vaccine. A major goal of vaccine development is the elicitation of antibodies capable of neutralizing diverse strains. In order to achieve this goal it is necessary to understand the dynamic relationship between neutralizing antibodies (NAbs) and HIV-1, in vivo. In humans, HIV-1 rapidly escapes from NAbs, confirming that humoral responses inhibit virus replication. However, neutralizing responses are commonly detected in viraemic patients and the clinical impact of NAbs on HIV-1 control is unclear. To investigate this further, viral load (VL) and NAb activity were assessed longitudinally in patients enrolled into a clinical trial of short-course antiretroviral therapy (ART), administered in early infection. The aims of this study were two-fold: i) to understand the importance of VL in the control of NAb responses and ii) to assess whether NAbs contribute to durable control of VL set-point. A high-throughput pseudovirus neutralization assay was developed, using automated counting procedures to quantify infected TZM-bl reporter cells. The assay was used to assess NAb responses with autologous viruses derived from 22 patients. Seven patients with low VL set-points (<104 RNA copies/ml) failed to develop neutralizing responses throughout the 48-144 week follow-up period. In contrast, the remaining patients developed progressively-increasing neutralizing plasma titres (IC50) that correlated with the extent and timing of VL rebound after cessation of ART. This suggests that the production of NAbs depends on the duration and extent of viraemia in early infection. Viral load was poorly predictive of neutralizing responses against heterologous isolates assayed in 38 patients, suggesting that other factors are important in the production of antibodies with cross-neutralizing activity. Depletion of specific immunological compartments can yield crucial information as to their functional importance in vivo. We took advantage of a unique opportunity to investigate the role of NAbs and the consequences of their depletion in an HIV-1 infected human. Three years after cessation of short-course ART, the patient was treated for pre-existing low-grade lymphoplasmacytic lymphoma by antibodymediated depletion of CD20+ B cells using rituximab. This treatment was followed by a 1.7 log10 rise in HIV-1 VL which spontaneously reversed. Autologous NAb responses decreased as viraemia flared, and recovered as VL was controlled. Antibodies were found to target the CD4 binding site (CD4bs), as shown by competitive-binding assays. Sequence analysis revealed diversification through generation of new variants as NAbs decreased, with subsequent selection of NAb-resistant mutants at sites consistent with the binding data. These data suggest that B cell function contributed to long-term control of VL in this individual and that NAbs may be more important in controlling HIV-1 infection than previously suspected.
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Jianchao. "HIV-1/SIV neutralizing antibody gene delivery a novel vaccination approach /." Columbus, Ohio : Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1237924213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lam, Sin Man. "Neutralizing antibodies and the biological response to interferon-beta therapy." Thesis, University of British Columbia, 2010. http://hdl.handle.net/2429/26977.

Full text
Abstract:
Interferon-beta (IFN-beta) was the first disease modifying drug to be approved for the treatment of multiple sclerosis (MS). IFN-beta reduces relapse rates, relapse severity as well as slows the progression of disease burden. However, neutralizing antibodies (NAbs) occur in a proportion of patients receiving IFN-beta treatment. NAbs bind to IFN-beta, reduce drug bioavailability and high levels of NAbs reduce drug efficiency. Our first objective was to develop and validate a sensitive and rapid method to measure NAbs. Existing methods to measure NAbs include the cytopathic effect assay (CPE) method and the myxovirus protein A (MxA) assay. However, these assays are time consuming and may be arduous to perform. We describe the optimization of a luciferase reporter gene assay to measure NAbs. To validate the assay, we assayed sera from IFN-beta treated MS patients with the optimized luciferase method and compared the results to those obtained with the reference CPE method. NAb status measured by the luciferase and the CPE method did not yield a significant difference. NAb titres obtained from the two methods correlated very well. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods. In addition to measuring NAbs, the biological activity of IFN-beta can be measured by monitoring IFN-inducible biomarkers, specifically MxA mRNA. Bioavailability measurements become especially valuable in patients with low to moderate NAb titres, “the grey zone”, and have been identified as a possible alternative for NAb measurements. Nonetheless, there is still controversy about how long should one wait after an IFN injection to draw blood for MxA mRNA measurements. Our objective was to identify the optimal time for blood draws to measure MxA mRNA. MxA mRNA was the most robust at 4-12 hours after IFN-beta injection and peaked at 8h post IFN injection. NAbs were evidently associated with an attenuation of IFN-beta bioactivity. In conclusion, we characterized a technique to assess NAbs associated with IFN-beta therapy and a method to assess IFN-beta biological activity in treated patients. Altogether, this will help measure the effects of IFN-beta treatment and assist clinicians in tailoring therapy to the individual patient.
APA, Harvard, Vancouver, ISO, and other styles
5

Burke, Karen L. "Antigen chimaeras of poliovirus." Thesis, University of Reading, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wiley, James A. "Monoclonal anti-idiotypes induce neutralizing antibodies to enterovirus-70 conformational epitopes." Thesis, University of Ottawa (Canada), 1992. http://hdl.handle.net/10393/7649.

Full text
Abstract:
The model pathogen used in the development of the anti-idiotypic antibodies produced in this project was enterovirus-70. This virus is the causative agent of acute hemorrhagic conjunctivitis. In the past twenty-five years, this virus has been responsible for two worldwide pandemics of acute hemorrhagic conjunctivitis. Monoclonal antibodies (MAbs), directed against the prototype enterovirus-70 strain, J670/71, were generated and characterized in order to produce a monoclonal anti-idiotypic antibodies (MAb2s) for use as surrogate immunogens. Radio-immunoprecipitation and western immunoblot assays suggested that all the monoclonal antibodies recognize conformational epitopes on the virion surface. A neutralizing monoclonal antibody, MAb/ev-12, was selected for the production of MAb2s. Five MAb2s were selected for their capacity to inhibit the interaction of MAb/ev-12 with EV-70 in dot immunobinding inhibition and immunofluorescence assays. These five MAb2s also inhibited virus neutralization mediated by MAb/ev-12 suggesting that each recognizes a paratope associated idiotope. In competition enzyme immunosorbent assays, none of the five MAb2s recognized other neutralizing and non-neutralizing enterovirus-70 specific MAbs, thus demonstrating that the MAb2s were specific for private idiotopes. Immunization with each of the MAb2s was carried out for the production of anti-anti-idiotypic antibodies (Ab3). All five MAb2s induced an immune response. Moreover, results suggested that they share idiotopes since MAb2:MAb/ev-12 binding could be inhibited by homologous as well as heterologous Ab3. Ab3 sera were shown to possess antibodies capable of immunoprecipitating $\sp{35}$S-labelled viral proteins in the same manner as MAb/ev-12. Nine of fifteen mice immunized with MAb2s demonstrated Ab3 neutralizing activity specific for the prototype EV-70 strain, J670/71. The potential application of MAb2s to serve as surrogate immunogens for conformational epitopes is substantiated by the results presented in this report.
APA, Harvard, Vancouver, ISO, and other styles
7

Derby, Nina Rafterman. "Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/9302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Alpert, Michael. "Antibodies in Vaccine Protection against SIV and HIV-1 Infection." Thesis, Harvard University, 2011. http://dissertations.umi.com/gsas.harvard:10057.

Full text
Abstract:
The properties of human immunodeficiency virus type 1 (HIV-1) and its simian counterpart SIV that enable persistent replication in the face of robust cellular, antibody, and innate immune responses have complicated efforts to develop a safe and effective vaccine. Vaccine protection against HIV-1 infection may require a combination of immune mechanisms. However, the types of immune responses that can be induced by vaccination to prevent HIV-1 infection remain unclear. The features of the viral envelope glycoprotein (Env) that confer inherent resistance to neutralization by antibodies also interfere with the development of antibody responses. We therefore vaccinated rhesus macaques with single-cycle SIV (scSIV) strains expressing Env proteins mutated to remove features that interfere with the induction of antibody responses. Antibodies capable of neutralizing Env-modified but not wild-type SIV were selectively enhanced. Identifying the immune responses underlying complete protection by live-attenuated SIV against pathogenic SIV challenge may provide guidance for HIV-1 vaccine design. To test the hypothesis that antibodies not measurable by assays for virus neutralization correlate with protection by live-attenuated SIV, we developed a novel assay for antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC activity increased progressively over time after inoculation, and was measurable against viruses expressing heterologous Env proteins from independent SIV isolates when neutralization was undetectable. Two separate pathogenic \(SIV_{mac}251\) challenge experiments took advantage of either the strain specificity or the time-dependent development of immunity to overcome complete protection by live-attenuated SIV. In both experiments, macaques inoculated with live-attenuated SIV that remained uninfected by \(SIV_{mac}251\) had significantly higher ADCC activity than those that became infected. We also measured ADCC for the primary immune correlates analysis of a recent HIV-1 vaccine clinical trial in Thailand (RV144) that reported modest vaccine protection (31%). There was a nonsignificant trend towards lower risk of infection among vaccinees with high versus low relative ADCC activity. However, Env-specific IgA correlated with risk, prompting an analysis stratified by IgA levels. Among vaccinees with low Env-specific IgA, there was lower risk of infection among those with higher ADCC activity. These observations suggest that antibodies that direct ADCC may contribute to vaccine protection against SIV and HIV-1 infection.
APA, Harvard, Vancouver, ISO, and other styles
9

Yari, Fayezeh. "Expression of recombinant neutralizing anti-HIV-1 antibodies in bacteria and eukaryotic cells /." Stockholm : Karolisnska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-079-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Molinos, Albert Luis Manuel. "Targeting a major HIV-1 vulnerability region: the gp41 membrane proximal external region. Balance between neutralizing and non-neutralizing antibodies and implications for vaccine design." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/392728.

Full text
Abstract:
La generació d’anticossos àmpliament neutralitzants contra el VIH-1 es el principal objectiu d’una vacuna que sigui capaç de controlar l’epidèmia causada per aquest virus. La glicoproteïna de l’embolcall del VIH-1 es l’únic antigen viral exposat a la membrana del virus y la principal diana de respostes humorals protectores. Dins d’aquesta proteïna han sigut identificades regions funcionals reconegudes per anticossos àmpliament neutralitzants, fent possible la definició de punts de vulnerabilitat del virus, cap als que una vacuna hauria de dirigir-se. En aquest context, la regió externa pròxima a la membrana (MPER) de la gp41 es un dels llocs de vulnerabilitat més representatius del virus, ja que està altament conservat, té un paper crucial per a la infectivitat del virus i es reconegut per anticossos protectors àmpliament neutralitzants. Tot i així, la seva situació, prop a la membrana, fa que el MPER sigui un domini poc accessible, exposat de manera transitòria, hidrofòbic i altament influenciat pels lípids de la membrana. Per tant, la seva immunogenicitat presenta una alta complexitat que ha de ser explorada en major profunditat. En aquesta tesi, aportem nou coneixement sobre l’immunogenicitat del MPER durant l´infecció natural i en models animals d’immunització. S’han avaluat miniproteïnes derivades de la gp41 que sobreexposen el MPER, per ser utilitzades com 1) nous plataformes per a la detecció d’anticossos anti-MPER i 2) prototipus d’immunògens presentats en proteoliposomes de diversa composició. Els resultats van revelar una alta immunogenicitat del MPER en humans, que correlaciona amb la resposta global contra la proteïna de l’embolcall, suggerint que el sistema immune no té cap restricció per a la generació d’aquest tipus d’anticossos. Tot i així, els anticossos detectats van mostrar una funcionalitat heterogènia, tant pel que fa a la capacitat neutralitzant com a la competició per diferents epítops, independentment de l’especificitat per MPER. A més, aquest resultats van ser reproduïts en animals immunitzats. En aquest últims, s’ha aconseguit generar un alt títol d’anticossos específics, que van ser potenciats per la incorporació als proteoliposomes de lípids complexes que mimetitzaven als de la partícula viral. Sorprenentment, es va generar una resposta immunodominant no neutralitzant contra un epítop solapant amb el de l’anticòs neutralitzant 2F5. En resum, la resposta humoral contra el MPER a humans i animals immunitzats no va correlacionar amb la capacitat neutralizant d’aquests i els anticossos generats són principalment no neutralitzants. Aquests resultats suggereixen que el balanç de la resposta neutralitzant i no neutralitzant té una important rellevància en la resposta global contra el MPER. Conseqüentment, sembla necessari un major refinament d’immunògens capaços d’evitar respostes no neutralitzants. Aquest redisseny es veurà altament beneficiat pel coneixement generat a partir de nous anticossos monoclonals contra el MPER que recullin l’heterogeneïtat funcional observada als nostres estudis.
La generación de anticuerpos ampliamente neutralizantes contra el VIH-1 es el principal objetivo de una vacuna que sea capaz de controlar la epidemia causada por el virus. La glicoproteína de la envuelta del VIH-1 es el único antígeno viral expuesto en la membrana del virus y la principal diana de respuestas humorales protectoras. Dentro de esta proteína se han identificado regiones funcionales que son reconocidas por anticuerpos ampliamente neutralizantes, lo cual ha permitido establecer puntos de vulnerabilidad del virus hacia los que una vacuna debería dirigirse. En este contexto, la región externa próxima a la membrana (MPER) de gp41 es uno de los sitios de vulnerabilidad del virus más representativos, ya que está altamente conservado, juega un papel crucial en la infectividad del virus y es reconocido por anticuerpos protectores ampliamente neutralizantes. Sin embargo, su localización, contigua a la membrana, hace del MPER un dominio poco accesible, expuesto de forma transitoria, hidrofóbico y altamente influenciado por lípidos de membrana. En consecuencia, su inmunogenicidad presenta una alta complejidad que debe ser explorada en mayor profundidad. En esta tesis, aportamos nuevo conocimiento sobre la inmunogenicidad del MPER a nivel de la infección natural y en modelos animales de inmunización. Hemos evaluado miniproteínas basadas en gp41 que sobreexponen el MPER, para ser utilizadas como 1) nuevas plataformas para la detección de anticuerpos anti-MPER y 2) prototipos de inmunógenos presentados en proteoliposomas de diversa composición. Los resultados han revelado una alta inmunogenicidad del MPER en humanos, que correlaciona con la respuesta global contra la proteína de la envuelta. Esto sugiere que el sistema inmune no tiene una especial restricción para la generación de este tipo de anticuerpos. Sin embargo, los anticuerpos detectados mostraron una funcionalidad heterogénea, en términos de capacidad neutralizante y competición por diferentes epítopos, independientemente de la especificidad por el MPER. Además, los resultados fueron reproducidos en animales inmunizados. En estos últimos, conseguimos generar un alto título de anticuerpos específicos, potenciados por la incorporación en los proteoliposomas de mezclas lipídicas complejas que mimetizaban las de la partícula viral. Sorprendentemente, se generó una respuesta inmunodominante no neutralizante que solapaba con un epítopo reconocido por el anticuerpo neutralizante 2F5. En resumen, la repuesta humoral natural contra el MPER en pacientes infectados por el VIH-1 y la generada en modelos animales mediante inmunización comparten ciertas características como son la especificidad y la escasa capacidad neutralizante. Estos resultados sugieren que el balance entre la respuesta neutralizante y no neutralizante podría tener una importante relevancia en la respuesta global contra el MPER. De este modo, es necesario un mayor refinamiento de inmunógenos que sean capaces de sortear respuestas no neutralizantes. Este rediseño se verá altamente beneficiado del conocimiento generado a partir de nuevos anticuerpos monoclonales contra el MPER que reflejen la heterogeneidad funcional observada en nuestros estudios.
The elicitation of broadly neutralizing antibodies (bNAbs) against HIV-1 constitutes the major goal of an effective vaccine able to control the epidemic caused by this virus. The HIV-1 envelope glycoprotein is the only viral antigen exposed on the surface of the virus and the main target of protective humoral responses. The identification within this protein of functional regions recognized by bNAbs has delineated an HIV-1 vulnerability map that has guided efforts for rational immunogen design. In this regard, the gp41 Membrane Proximal External Region (MPER) is a major HIV-1 vulnerability site because is highly conserved, plays a major role in viral infectivity and is targeted by protective bNAbs. However, its localization, next to the viral membrane, results in a hardly accessible, transiently exposed and hydrophobic domain, strongly influenced by membrane lipids. Therefore, the immunogenicity of the MPER offers a high level of complexity that needs to be further explored. In this thesis we provide new knowledge on the MPER immunogenicity in both natural HIV-1 infection and immunization in animal models. We generated gp41-based miniproteins which properly exposed the MPER region that have been used 1) as novel platforms for MPER antibody detection and 2) as immunogen candidates presented in different proteoliposome compositions. In humans, the results revealed a strong immunogenicity of the MPER that correlated with a global response against the envelope glycoprotein suggesting no special constraints for the immune system to target this region. However, the antibodies elicited showed heterogeneous functionality in terms of neutralizing capacity and epitope competition, regardless MPER specificity. Interestingly, these results were reproduced by immunization in animal models. High antibody titers were achieved that were specially enhanced by the addition of lipid mixtures mimicking the viral membrane. Interestingly, a non-neutralizing immunodominant response against an epitope that overlapped the 2F5 neutralizing antibody binding motif was identified. Overall, the anti-MPER response in both humans and animal model settings was not correlated with the neutralizing capacity and antibodies detected or induced by immunization were preferentially non-neutralizing. Our results suggest that the balance between neutralizing and non neutralizing responses may represent an important issue in the global response against MPER. Therefore, further redesign of immunogens able to skip non-neutralizing determinants will benefit from the knowledge derived from new anti-MPER antibodies that reflect the functional heterogeneous profile observed in our studies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Neutralizing antibodies"

1

Tovey, Michael G. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, N.J: Wiley, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

O'Rourke, Katherine. Neutralizing and cross neutralizing antibodies in horses with equine infectious anemia virus. 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chiodi, Francesca, and Gabriella Scarlatti, eds. HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies. Frontiers Media SA, 2018. http://dx.doi.org/10.3389/978-2-88945-461-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schommers, Philipp, Harry Gristick, Marit J. Van Gils, and Kshitij Wagh, eds. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Limited, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel, and M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.

Full text
Abstract:
While the HIV/AIDS pandemic continues, the overall incidence of HIV infections has fallen through use of antiretroviral therapy (ART) and multiple prevention modalities. To achieve a durable end to the pandemic and avoid the requirement for daily antiretroviral medication over a lifetime, a safe and effective prophylactic vaccine remains essential. This chapter reviews current advances in prophylactic and therapeutic HIV-1 vaccine strategies and the challenges that lie ahead. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs) from infected individuals, the discovery of mechanisms of bnAb induction, and progress in understanding mechanisms of CD8 T-cell killing of HIV-infected cells and the structure of the HIV envelope trimer have opened new strategies for HIV vaccine design. On the therapeutic front, the persistence of HIV reservoirs remains a formidable obstacle to achieving sustained virological remission in HIV-infected individuals after ART is discontinued. Development of a new generation of immune-based therapeutic agents might contribute to a curative intervention. The chapter closes with an overview of ethical challenges in vaccine development and clinical testing.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Neutralizing antibodies"

1

Robert-Guroff, Marjorie. "Neutralizing Antibodies." In Techniques in HIV Research, 179–85. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11888-5_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kunert, Renate. "The Neutralizing Anti-HIV Antibody 2G12." In Anticarbohydrate Antibodies, 147–60. Vienna: Springer Vienna, 2011. http://dx.doi.org/10.1007/978-3-7091-0870-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Suitters, Amanda, and Roly Foulkes. "Cytokine-neutralizing therapeutic antibodies." In Novel Cytokine Inhibitors, 123–43. Basel: Birkhäuser Basel, 2000. http://dx.doi.org/10.1007/978-3-0348-8450-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moulard, Maxime, Mei-Yun Zhang, and Dimiter S. Dimitrov. "Novel Hiv Neutralizing Antibodies Selected from Phage Display Libraries." In Antibodies, 105–17. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-8877-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Abraham, Edward. "Neutralizing antibodies and receptor constructs." In Cytokines in Severe Sepsis and Septic Shock, 285–93. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8755-7_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lansky, David, and Carrie Wager. "Dilutional Linearity for Neutralizing Antibody Assays." In Detection and Quantification of Antibodies to Biopharmaceuticals, 309–17. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118075685.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ruprecht, Ruth M. "Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches." In Therapeutic Antibodies, 559–66. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Mei-Yun, and Dimiter S. Dimitrov. "Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41." In Therapeutic Antibodies, 175–86. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grossberg, Sidney E., and Yoshimi Kawade. "The Expression of Potency of Neutralizing Antibodies for Interferons and other Cytokines." In Antibodies in Cytokines, 93–98. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5664-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Xueling. "HIV Broadly Neutralizing Antibodies: VRC01 and Beyond." In HIV Vaccines and Cure, 53–72. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Neutralizing antibodies"

1

Morton, Scott P., and Joshua L. Phillips. "pH Dependent Binding Energies of Broadly Neutralizing Antibodies." In 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Johnsson, H., A. Silveira, L. Adamson, S. Schulman, and B. Hessel. "INDUCED ANTIBODIES TO VON WILLEBRAND FACTOR (VWF)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644112.

Full text
Abstract:
Plasma from 11 patients have been investigated for the presence of antibodies to VWF using an immunoblot-ting system. Eight patients had severe haemophilia A and 3 had severe VW's disease (VWD). One haemophiliac had a high titer of neutralizing activity against VIII:C, and two had previously shown neutralizing activity against VIII:C. Neutralizing activity against ristocetin cofactor was demonstrated in only two of the VWD-patients. None of the VWD-patients did show antiactivity to VIII:C. All patients except 2 haemophiliacs had been transfused with factor concentrate within the last three weeks before blood sampling. Four different concentrates had been used.The following immunoblotting system was used: Highly purified VWF was applied to agarose gels, and electrophoresis performed. The proteins were blotted to nitrocellulose paper and the paper cut into strips. The strips were incubated with diluted plasma or the IgG-fraction of plasma (obtained by precipitation with ammoniumsulphate) from one or the other of the patients. Thereafter, the strips were treated with a second antibody (goat-anti human IgG) labeled with peroxidase before development with α-chloronaphtol. As a negativ control, normal plasma was used. As a positive control, a peroxidase labeled goat-antihuman VWF was used giving the known multimeric pattern of VWF-antigen.Antibodies to VWF were found in 4 haemophiliacs and in all 3 VWD-patients. The pattern of multimeric bands obtained with the antibodies showed differences in different patients. The in vivo t 1/2 of VIII:C concentrate did not seem to be affected by these antibodies to VWF.
APA, Harvard, Vancouver, ISO, and other styles
3

Solodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov, et al. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.

Full text
Abstract:
The late stage of the COVID-19 pandemic is marked by the appearance of mutant variants of SARS-CoV-2 that can escape the immunity against the Wuhan virus. In this work, we report on the development of a panel of antiviral agents — single-domain antibodies that recognize independent epitopes of the SARS-CoV-2 S protein. Four antibodies from this panel neutralize a wide range of virus variants, including the most common ones at present: XBB.1.5 and XBB.1.16.
APA, Harvard, Vancouver, ISO, and other styles
4

Sun, Jing, Guang Lan Zhang, Lars Rønn Olsen, Ellis L. Reinherz, and Vladimir Brusic. "Landscape of neutralizing assessment of monoclonal antibodies against dengue virus." In BCB'13: ACM-BCB2013. New York, NY, USA: ACM, 2013. http://dx.doi.org/10.1145/2506583.2512359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dias, Brenda, Andrea Silva, Ariane Souza, Luma Moura, Nathália Alves, Vanessa Rocha, Ana Argondizzo, Sheila Lima, Helena Toma, and Adriana Azevedo. "Neutralizing antibodies and igg avidity against SARS-CoV-2 variants." In International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2023. http://dx.doi.org/10.35259/isi.2023_58035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kent, Michael, Maxwell Stefan, Brooke Harmon, Daniel Gelperin, Valerie Duva, Alyssa Wynne, and Valeria Busygina. "Rapidly Adapting Neutralizing Antibodies to Related Virus Types and Subtypes." In Proposed for presentation at the Biophysical Society Annual Meeting 2021 held February 22-26, 2021. US DOE, 2021. http://dx.doi.org/10.2172/1842569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gavrilova, N. V., V. V. Vysochinskaya, E. A. Elpaeva, O. A. Dobrovolskaya, M. A. Plotnikova, A. A. Lozhkov, E. L. Zimmerman, A. A. Shaldzhyan, and Y. A. Zabrodskaya. "ANTIVIRAL ACTIVITY OF MRNAS ENCODING ANTIBODIES, TARGETING INFLUENZA A HEMAGGLUTININ AND INFLUENZA B NUCLEOPROTEIN IN VITRO." In OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-239.

Full text
Abstract:
Influenza poses a significant public health concern, and the development of therapeutic antibodies provides a promising avenue for its treatment. In this study, we generated mRNA sequences encoding neutralizing antibodies targeting the hemagglutinin of influenza A virus, as well as antibodies specific to the nucleoprotein of influenza B virus. We successfully demonstrated the antiviral activity of mRNA-encoded antibodies targeting the hemagglutinin against influenza A virus in vitro.
APA, Harvard, Vancouver, ISO, and other styles
8

Rak, A. Ya, Ya A. Zabrodskaya, N. P. Gorbunov, D. S. Polyakov, D. A. Mezhenskaya, L. G. Rudenko, and I. N. Isakova-Sivak. "DEVELOPMENT OF A UNIVERSAL DIAGNOSTIC TEST SYSTEM FOR DETERMINING THE TITER OF ANTIBODIES AGAINST SARS-COV-2 BY MICRONEUTRALIZATION." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-226.

Full text
Abstract:
The study proposes a unique test system for determining the titer of neutralizing antibodies against various SARS-CoV-2 strains, including biotinylated monoclonal antibodies against the nucleocapsid protein and the recombinant streptavidin-GFP fusion protein. The key advantages of its use are high sensitivity, simplicity and low cost of analysis, the universality of detection of different coronavirus variants, and the possibility of adaptation to detect other antigens when using appropriate antibodies.
APA, Harvard, Vancouver, ISO, and other styles
9

Allaf, L. Al, A. Chechushkov, T. Ushakova, V. Morozova, and N. Tikunova. "INFLUENCE OF HUMORAL IMMUNE RESPONSE TO BACTERIOPHAGE ON PHAGE-THERAPY AND ANTI-BACTERIAL IMMUNITY." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-223.

Full text
Abstract:
We demonstrated that although phage therapy with PM16 leads to the formation of anti-phage neutralizing antibodies in balb/c mice, it may boost the organism humoral response against its host, p. mirabilis. On the other hand, injecting balb/c mice with p.mirabilis increases the level of anti-PM16 antibodies, even in mice without previous encounter with PM16.
APA, Harvard, Vancouver, ISO, and other styles
10

Zimonina, A. A., E. Yu Prudnikova, and A. R. Imatdinov. "RECOMBINANT MONOCLONAL ANTIBODIES WITH VIRUS NEUTRALIZING ACTIVITY AGAINST SARS-COV-2 DELTA AND OMICRON VARIANTS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-81.

Full text
Abstract:
The study describes the production and characterization of recombinant human monoclonal antibodies interacting with the receptor-binding domain of the Spike glycoprotein and possessing virus-neutralizing activity against SARS-CoV-2 variants Delta and Omicron.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Neutralizing antibodies"

1

Glassy, Mark C. Neutralizing Monoclonal Antibodies against Biological Toxins. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, August 1993. http://dx.doi.org/10.21236/adb176298.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ivanova, Sonya, Raliza Skrobanska, Vera Kolyovska, and Ivan Milanov. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients? "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, August 2018. http://dx.doi.org/10.7546/crabs.2018.08.17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ivanova, Sonya, Raliza Skrobanska, Vera Kolyovska, Ivan Milanov, Valentina Dimitrova, and Veneta Bojinova. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, September 2018. http://dx.doi.org/10.7546/crabs.2018.09.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mogler, Mark, and D. L. Hank Harris. Passive Immunization of Piglets Using Equine Plasma Containing PRRS Virus-Neutralizing Antibodies. Ames (Iowa): Iowa State University, January 2008. http://dx.doi.org/10.31274/ans_air-180814-171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kaniewski, Laura, Jason Hocker, Mark Mogler, Matthew M. Erdman, Eric Nelson, and D. L. Hank Harris. Passive Immunization of Piglets with Hyperimmune Plasma Containing Virus Neutralizing Antibodies to Porcine Reproductive and Respiratory Syndrome Virus. Ames (Iowa): Iowa State University, January 2009. http://dx.doi.org/10.31274/ans_air-180814-65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mackey, Katherine, Irina Arkhipova-Jenkins, Charlotte Armstrong, Emily Gean, Johanna Anderson, Robin A. Paynter, and Mark Helfand. Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review. Agency for Healthcare Research and Quality (AHRQ), March 2021. http://dx.doi.org/10.23970/ahrqepccovidimmunity.

Full text
Abstract:
 Evidence suggests that the majority of adults develop detectable levels of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies following infection with SARS-CoV-2 (moderate strength of evidence* [SoE]).  IgM levels peak approximately 20 days after symptom onset or RT-PCR diagnosis and subsequently decline. IgG levels peak approximately 25 days after symptom onset or RT-PCR diagnosis and may remain detectable for at least 120 days (moderate SoE*).  Almost all adults develop neutralizing antibodies in response to SARS-CoV-2 infection, and these antibodies may remain detectable for at least 152 days (low SoE*).  A small percentage of people do not develop antibodies in response to SARS-CoV-2 infection for reasons that are largely unclear but may be related to less severe disease or absence of symptoms.  Antibody prevalence does not appear to vary by age or sex, but older age may be associated with higher antibody levels (low SoE*). Non-White race may be associated with higher antibody prevalence and levels (low SoE*). COVID-19 severity and presence of symptoms may also be associated with higher antibody prevalence or levels (low SoE*). More evidence is needed to draw stronger conclusions regarding how the antibody response varies by patient characteristics and disease factors.  Studies to date have not established the relationship between the development of antibodies after RT-PCR-diagnosed SARS-CoV-2 infection and the risk of reinfection. Studies based on index serologic testing suggest that the presence of antibodies is associated with a lower risk of a subsequent positive SARS-CoV-2 RT-PCR test.
APA, Harvard, Vancouver, ISO, and other styles
7

Juni, Peter, Ashleigh R. Tuite, Issac I. Bogoch, Adalsteinn D. Brown, Yoojin Choi, Bruno R. da Costa, Gerald A. Evans, et al. Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario. Ontario COVID-19 Science Advisory Table, January 2021. http://dx.doi.org/10.47326/ocsat.2021.02.06.1.0.

Full text
Abstract:
Administering Pfizer-BioNTech’s COVID-19 vaccine during the early stage of the vaccine rollout (January/February 2021) to as many individuals as possible would prevent more COVID-19 cases in Ontario as compared to reserving half of the initial allotments as second booster doses (Figure 1). On-label use of the vaccine with the administration of two doses is important, as the second dose significantly boosts the immune response and results in a substantial increase in neutralizing antibodies. However, using 100% of the initial allotments immediately to vaccinate as many individuals as possible does not preclude on-label use with two doses, even though the interval between first and second booster dose may become longer than 21 days.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Neutralizing antibodies' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography